Since depression impacts all body systems, antidepressant treatments should relieve both
the emotional and physical symptoms of depression. Duloxetine demonstrated …

Objectives: Patients with major depressive disorder (MDD) and a comorbid anxiety disorder
or significant anxiety symptoms have decreased functioning, increased risk of suicidality …

BACKGROUND: Patients with depression often experience pain. There is limited
understanding of the relation between pain and other symptoms (depressive, anxious and …

Background. It is widely believed that most antidepressant medications exhibit a delay of 2–
4 weeks before clinically relevant improvement can be observed among patients. During this …

Background: Second-generation antidepressants dominate the management of patients with
major depressive disorder (MDD). Evidence on the general and comparative benefits and …

Duloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor that has been
recently approved for the treatment of major depressive disorder (MDD). However, little is …

This study compared the stabilized duloxetine dose through approximately 12 weeks of
treatment in patients initiating duloxetine therapy with that in patients switching to duloxetine …

Background: To identify putative demographic and clinical variables that correlate with
antidepressant response to the SNRI duloxetine in major depression. Methods: The effect of …

The primary objectives of this study were to assess the efficacy and safety of duloxetine for
reducing pain severity in fibromyalgia patients with or without current major depressive …

Background Duloxetine has been studied in four distinct chronic pain conditions–
osteoarthritis (OA), fibromyalgia, chronic low back pain (CLBP) and diabetic peripheral …